ALS Research Collaboration
  • Home
  • About Us
    • Who we are
    • Our Approach
    • Our Team
    • Our History
  • Our Research
    • Research Focus
    • Participate
    • Studies
    • Current
    • Completed
    • All
    • Publications & Talks
    • Research Vignettes
  • News & Events
  • Support Us
    • Make a donation
  • Contact Us
Select Page

Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology.

by Alexandra Grace | Dec 2, 2025

Kvam KA, Benatar M, Brownlee A, Caller T, Das RR, Green P, Kolodziejczak S, Russo J, Sanders D, Sethi N, Stavros K, Stierwalt J, Giles Walters N, Bennett A, Wessels SR, Brooks BR. Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement...

CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro

by Alexandra Grace | Dec 2, 2025

Meijboom KE, Abdallah A, Fordham NP, Nagase H, Rodriguez T, Kraus C, Gendron TF, Krishnan G, Esanov R, Andrade NS, Rybin MJ, Ramic M, Stephens ZD, Edraki A, Blackwood MT, Kahriman A, Henninger N, Kocher JA, Benatar M, Brodsky MH, Petrucelli L, Gao FB, Sontheimer EJ,...

Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.

by Alexandra Grace | Nov 22, 2024

Koch JC, Leha A, Bidner H, Cordts I, Dorst J, Günther R, Zeller D, Braun N, Metelmann M, Corcia P, De La Cruz E, Weydt P, Meyer T, Großkreutz J, Soriani MH, Attarian S, Weishaupt JH, Weyen U, Kuttler J, Zurek G, Rogers ML, Feneberg E, Deschauer M, Neuwirth C, Wuu J,...

Body mass index is lower in asymptomatic C9orf72 expansion carriers but not in SOD1 pathogenic variant carriers compared to gene negatives.

by Alexandra Grace | Nov 22, 2024

Lee I, Garret MA, Wuu J, Harrington EA, Berry JD, Miller TM, Harms M, Benatar M, Shneider N. Body mass index is lower in asymptomatic C9orf72 expansion carriers but not in SOD1 pathogenic variant carriers compared to gene negatives. Amyotroph Lateral Scler...

Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis.

by Alexandra Grace | Oct 2, 2024

Benatar M, Macklin EA, Malaspina A, Rogers ML, Hornstein E, Lombardi V, Renfrey D, Shepheard S, Magen I, Cohen Y, Granit V, Statland JM, Heckmann JM, Rademakers R, McHutchison CA, Petrucelli L, McMillan CT, Wuu J; CReATe Consortium PGB1 Study Investigators. ...
« Older Entries
Next Entries »

Recent Posts

  • Landmark Study Identifies Novel Pre-Symptomatic Biomarkers and Accelerates Progress Towards ALS Prevention
  • July 26, 2026: Miami Marlins Game
  • Feature: UHealth’s Qalsody Clinic Provides Cutting-Edge Care for ALS Patients
  • The New York Times Feature: In a Milestone for A.L.S., a Treatment Helps Some Patients Improve
  • CReATe Author Series Ep. 18 – Dr. Michael Benatar on MMI as a prodromal stage of ALS

Recent Comments

    Latest News

    07/27/26

    Landmark Study Identifies Novel Pre-Symptomatic Biomarkers and Accelerates Progress Towards ALS Prevention

    07/22/26

    July 26, 2026: Miami Marlins Game

    05/26/26

    Feature: UHealth’s Qalsody Clinic Provides Cutting-Edge Care for ALS Patients

    How You Can Help

    Participate in Research

    Make a Donation

    ALS Research Collaboration
    University of Miami,
    Department of Neurology
    1120 NW 14th Street
    Miami, FL 33136

    Search our site

    About Us

    • Who We Are
    • Our Approach
    • Our Team
    • Our History

    Our Research

    • Research Focus
    • Participate
    • All Studies
    • Publications and Talks
    • Research Vignettes

    Support Us

    • Make a Donation

    Search our site

    Copyright 2024 ALS Research Collaboration at University of Miami. All Rights Reserved. Branding by MOK2